Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialNEAL FRANZ, David; BELOUSOVA, Elena; CURATOLO, Paolo et al.Lancet (British edition). 2013, Vol 381, Num 9861, pp 125-132, issn 0140-6736, 8 p.Article

Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignanciesJONES, Suzanne; HAINSWORTH, John; BURRIS, Howard A et al.Investigational new drugs. 2002, Vol 20, Num 1, pp 55-61, issn 0167-6997, 7 p.Article

Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK) : translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastasesLEE, Lucy; SHARMA, Sunil; DREVS, Joachim et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 6, pp 761-771, issn 0344-5704, 11 p.Article

A phase II trial of JM-216 in cervical cancer: An NCIC CTG studyTRUDEAU, Marc; STUART, Gavin; HIRTE, Hal et al.Gynecologic oncology (Print). 2002, Vol 84, Num 2, pp 327-331, issn 0090-8258Article

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2GNANT, Michael; BASELGA, Jose; GEBERTH, Matthias et al.Journal of the National Cancer Institute. 2013, Vol 105, Num 9, pp 654-663, issn 0027-8874, 10 p.Article

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trialBISSLER, John J; CHRISTOPHER KINGSWOOD, J; WHITTEMORE, Vicky H et al.Lancet (British edition). 2013, Vol 381, Num 9869, pp 817-824, issn 0140-6736, 8 p.Article

Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast CancerBASELGA, Jose; CAMPONE, Mario; THADDEUS BECK, J et al.The New England journal of medicine. 2012, Vol 366, Num 6, pp 520-529, issn 0028-4793, 10 p.Article

Future directions in the treatment of hormone-sensitive advanced breast cancer : The RAD001 (everolimus)-letrozole clinical programLANE, Heidi A; LEBWOHL, David.Seminars in oncology. 2006, Vol 33, Num 2, issn 0093-7754, S18-S25, SUP7Article

Phase III study of N, N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19REYNO, Leonard; SEYMOUR, Lesley; PIENKOWSKI, Tadeusz et al.Journal of clinical oncology. 2004, Vol 22, Num 2, pp 269-276, issn 0732-183X, 8 p.Article

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 StudyOHTSU, Atsushi; AJANI, Jaffer A; MURO, Kei et al.Journal of clinical oncology. 2013, Vol 31, Num 31, pp 3935-3943, issn 0732-183X, 9 p.Article

A Phase IA, Open-label, Dose-escalating Study of PTK787/ZK 222584 Administered Orally on a Continuous Dosing Schedule in Patients with Advanced CancerDREVS, Joachim; MEDINGER, Michael; LAURENT, Dirk et al.Anticancer research. 2010, Vol 30, Num 6, pp 2335-2339, issn 0250-7005, 5 p.Article

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapyVANSTEENKISTE, Johan; LARA, Primo N; PECK, Ronald et al.Journal of clinical oncology. 2007, Vol 25, Num 23, pp 3448-3455, issn 0732-183X, 8 p.Article

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412STONE, Richard M; DEANGELO, Daniel J; FOX, Edward A et al.Blood. 2005, Vol 105, Num 1, pp 54-60, issn 0006-4971, 7 p.Article

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five daysABRAHAM, Jame; AGRAWAL, Manish; LEBWOHL, David et al.Journal of clinical oncology. 2003, Vol 21, Num 9, pp 1866-1873, issn 0732-183X, 8 p.Article

Everolimus Plus Exemestane in Postmenopausal Patients with HR⁺ Breast Cancer: BOLERO-2 Final Progression-Free Survival AnalysisYARDLEY, Denise A; NOGUCHI, Shinzaburo; MELICHAR, Bohuslav et al.Advances in therapy. 2013, Vol 30, Num 10, pp 870-884, issn 0741-238X, 15 p.Article

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyPAVEL, Marianne E; HAINSWORTH, John D; ÖBERG, Kjell et al.Lancet (British edition). 2011, Vol 378, Num 9808, pp 2005-2012, issn 0140-6736, 8 p.Article

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II TrialYAO, James C; LOMBARD-BOHAS, Catherine; VAN CUTSEM, Eric et al.Journal of clinical oncology. 2010, Vol 28, Num 1, pp 69-76, issn 0732-183X, 8 p.Article

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapyAWADA, Ahmad; PICCART, Martine J; JONES, Suzanne F et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 3, pp 417-425, issn 0344-5704, 9 p.Article

Dose-and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus : A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid TumorsTABERNERO, Josep; ROJO, Federico; SHAND, Nicholas et al.Journal of clinical oncology. 2008, Vol 26, Num 10, pp 1603-1610, issn 0732-183X, 8 p.Article

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancerTHOMAS, Eva; TABERNERO, Josep; BASELGA, José et al.Journal of clinical oncology. 2007, Vol 25, Num 23, pp 3399-3406, issn 0732-183X, 8 p.Article

Everolimus for Advanced Pancreatic Neuroendocrine TumorsYAO, James C; SHAH, Manisha H; TOMASSETTI, Paola et al.The New England journal of medicine. 2011, Vol 364, Num 6, pp 514-523, issn 0028-4793, 10 p.Article

Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal AdenocarcinomaHECHT, J. Randolph; TRARBACH, Tanja; CHEN, Bee-Lian et al.Journal of clinical oncology. 2011, Vol 29, Num 15, pp 1997-2003, issn 0732-183X, 7 p.Article

Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal AdenocarcinomaVAN CUTSEM, Eric; BAJETTA, Emilio; LEBWOHL, David et al.Journal of clinical oncology. 2011, Vol 29, Num 15, pp 2004-2010, issn 0732-183X, 7 p.Article

Efficacy of everolimus in advanced renal cell carcinoma : a double-blind, randomised, placebo-controlled phase III trial. CommentaryKNOX, Jennifer J; MOTZER, Robert J; HOLLAENDER, Norbert et al.Lancet (British edition). 2008, Vol 372, Num 9637, issn 0140-6736, 427-429, 449-456 [11 p.]Article

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone b analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapyROCHE, Henri; YELLE, Louise; LEBWOHL, David et al.Journal of clinical oncology. 2007, Vol 25, Num 23, pp 3415-3420, issn 0732-183X, 6 p.Article